Physician profile
Brynith Stocker
NPI 1518414093
$3,435.23
in general payments reported to CMS, 2019-2025
24 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.92 · 2022: $200 · 2023: $2,951 · 2024: $125 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,930 · Honoraria: $1,000 · Travel and Lodging: $204 · Education: $66.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,930.11 |
| Honoraria | $1,000.00 |
| Travel and Lodging | $204.27 |
| Education | $66.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $1,414.18 | 2023 | Cosela |
| Janssen Biotech, INC. | $1,065.75 | 2023-2025 | Darzalex, Carvykti, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $236.07 | 2023 | Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $162.80 | 2022-2023 | |
| Emd Serono, INC. | $61.50 | 2023 | Bavencio, Tepmetko |
| Incyte Corporation | $50.97 | 2022-2023 | Monjuvi, Pemazyre |
| Amgen INC. | $35.91 | 2021-2023 | Kyprolis |
| Foundation Medicine, INC. | $35.07 | 2022 | |
| Celgene Corporation | $34.04 | 2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $31.71 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $28.79 | 2023 | Epkinly |
| Progenics Pharmaceuticals, INC. | $28.73 | 2023 | Pylarify |
| Coherus Oncology, INC. | $27.12 | 2022-2023 | |
| Daiichi Sankyo INC. | $27.09 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.81 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $24.53 | 2022 | |
| Genentech USA, INC. | $23.20 | 2023 | Venclexta |
| Exelixis INC. | $21.81 | 2023 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $21.52 | 2023 | Libtayo |
| Myriad Genetic Laboratories, INC. | $20.95 | 2023 | Myrisk |
| Clovis Oncology, INC. | $19.80 | 2022 | |
| Pfizer INC. | $13.44 | 2023 | |
| Taiho Oncology, INC. | $12.93 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brynith Stocker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.